問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 251New Taipei CityDanshuei

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

256Cases

2007-12-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2008-05-01 - 2009-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-10-15 - 2012-01-02

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-10-15 - 2008-10-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Condition/Disease

    Obesity

  • Test Drug

    Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2010-03-03 - 2010-12-31

Phase III

A pan-Asian clinical trial comparing the efficacy and safety of insulin NN1250 and insulin glargin in patients with type 2 diabetes who are currently using oral hypoglycemic drugs. A 26-week, randomized, confirmatory, controlled, open-ended, multi-center, multi-country, clinical trial that achieves the treatment goals, comparing SIBA and insulin glargine injected once a day with oral hypoglycemic drugs for type 2 diabetes The efficacy and safety of patients.

  • Condition/Disease

    Diabetes

  • Test Drug

    Insulin 454 (SIBA) 100 U/ml, 3 mL prefilled pen, solution for injection

Participate Sites
8Sites

Terminated8Sites

2016-05-06 - 2017-08-16

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-05-01 - 2013-04-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-04-01 - 2017-03-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-10-01 - 2010-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 20 21 22 23 24 26
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB